| Local structural elements in the mostly unstructured transcriptional activation domain of human p53 H Lee, KH Mok, R Muhandiram, KH Park, JE Suk, DH Kim, J Chang, ... Journal of Biological Chemistry 275 (38), 29426-29432, 2000 | 394 | 2000 |
| Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2 N Drayman, JK DeMarco, KA Jones, SA Azizi, HM Froggatt, K Tan, ... Science 373 (6557), 931-936, 2021 | 220 | 2021 |
| A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease SS Hayek, KH Koh, ME Grams, C Wei, YA Ko, J Li, B Samelko, H Lee, ... Nature medicine 23 (8), 945-953, 2017 | 213 | 2017 |
| Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein− ligand X-ray structure and biological evaluation AK Ghosh, J Takayama, KV Rao, K Ratia, R Chaudhuri, DC Mulhearn, ... Journal of medicinal chemistry 53 (13), 4968-4979, 2010 | 172 | 2010 |
| Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity Z Shen, K Ratia, L Cooper, D Kong, H Lee, Y Kwon, Y Li, S Alqarni, ... Journal of medicinal chemistry 65 (4), 2940-2955, 2021 | 168 | 2021 |
| Structure and function of the phosphothreonine-specific FHA domain A Mahajan, C Yuan, H Lee, ESW Chen, PY Wu, MD Tsai Science signaling 1 (51), re12-re12, 2008 | 167 | 2008 |
| Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus H Lee, J Ren, S Nocadello, AJ Rice, I Ojeda, S Light, G Minasov, J Vargas, ... Antiviral research 139, 49-58, 2017 | 144 | 2017 |
| Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV H Lee, H Lei, BD Santarsiero, JL Gatuz, S Cao, AJ Rice, K Patel, ... ACS chemical biology 10 (6), 1456-1465, 2015 | 140 | 2015 |
| Rufomycin targets ClpC1 proteolysis in Mycobacterium tuberculosis and M. abscessus MP Choules, NM Wolf, H Lee, JR Anderson, EM Grzelak, Y Wang, R Ma, ... Antimicrobial agents and chemotherapy 63 (3), 10.1128/aac. 02204-18, 2019 | 108 | 2019 |
| Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators AD Jain, H Potteti, BG Richardson, L Kingsley, JP Luciano, AF Ryuzoji, ... European journal of medicinal chemistry 103, 252-268, 2015 | 103 | 2015 |
| Diphosphothreonine-specific interaction between an SQ/TQ cluster and an FHA domain in the Rad53-Dun1 kinase cascade H Lee, C Yuan, A Hammet, A Mahajan, ESW Chen, MR Wu, MI Su, ... Molecular cell 30 (6), 767-778, 2008 | 95 | 2008 |
| Airway epithelial cell-derived colony stimulating factor-1 promotes allergen sensitization HG Moon, S Kim, JJ Jeong, SS Han, NN Jarjour, H Lee, ... Immunity 49 (2), 275-287. e5, 2018 | 77 | 2018 |
| Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro R Du, L Cooper, Z Chen, H Lee, L Rong, Q Cui Antiviral research 190, 105075, 2021 | 69 | 2021 |
| Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings H Lee, A Mittal, K Patel, JL Gatuz, L Truong, J Torres, DC Mulhearn, ... Bioorganic & medicinal chemistry 22 (1), 167-177, 2014 | 69 | 2014 |
| Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases Z Chen, Q Cui, L Cooper, P Zhang, H Lee, Z Chen, Y Wang, X Liu, L Rong, ... Cell & Bioscience 11, 1-8, 2021 | 66 | 2021 |
| High-resolution structure of ClpC1-rufomycin and ligand binding studies provide a framework to design and optimize anti-tuberculosis leads NM Wolf, H Lee, MP Choules, GF Pauli, R Phansalkar, JR Anderson, ... ACS infectious diseases 5 (6), 829-840, 2019 | 62 | 2019 |
| Targeting SARS‐CoV‐2 viral proteases as a therapeutic strategy to treat COVID‐19 V Anirudhan, H Lee, H Cheng, L Cooper, L Rong Journal of medical virology 93 (5), 2722-2734, 2021 | 59 | 2021 |
| Reducing agents affect inhibitory activities of compounds: results from multiple drug targets H Lee, J Torres, L Truong, R Chaudhuri, A Mittal, ME Johnson Analytical biochemistry 423 (1), 46-53, 2012 | 49 | 2012 |
| Hit-to-Lead: hit validation and assessment KE Hevener, R Pesavento, JH Ren, H Lee, K Ratia, ME Johnson Methods in Enzymology 610, 265-309, 2018 | 46 | 2018 |
| Allosteric inhibitors of the main protease of SARS-CoV-2 SK Samrat, J Xu, X Xie, E Gianti, H Chen, J Zou, JG Pattis, K Elokely, ... Antiviral research 205, 105381, 2022 | 41 | 2022 |
Michael E. JohnsonProfessor Emeritus, University of Illinois at ChicagoAdresse e-mail validée de uic.edu